Mortality and unadjusted and adjusted mortality risk in relation to eGFR
| eGFR≥90 n=5251 | eGFR 60–89 n=18 240 | eGFR 30–59 n=19 016 | eGFR 15–29 n=4252 | eGFR<15 n=813 | p Value | |
|---|---|---|---|---|---|---|
| All patients | ||||||
| In hospital (%) n=32 108 | 2% | 2% | 4% | 12% | 30% | <0.001 |
| At 6 months (%) n=47 636 | 5% | 8% | 16% | 35% | 53% | <0.001 |
| At 1 year (%) n=47 636 | 7% | 13% | 23% | 46% | 62% | <0.001 |
| Long-term (HR) unadjusted | 1 | 1.85 (1.73 to 1.97) | 3.57 (3.35 to 3.80) | 7.72 (7.20 to 8.28) | 11.71 (10.62 to 12.90) | <0.001 |
| Model 1 (HR) (n=47 545) | 1 | 0.83 (0.77 to 0.89) | 1.13 (1.05 to 1.21) | 2.12 (1.96 to 2.29) | 4.19 (3.79 to 4.64) | <0.001 |
| Model 2 (HR)(n=27 304) | 1 | 0.84 (0.74 to 0.92) | 1.10 (1.00 to 1.20) | 1.87 (1.68 to 2.08) | 3.26 (2.79 to 3.80) | <0.01 for all comparisons with eGFR ≥90 |
| Model 3 (HR)(n=27 302) | 1 | 0.86 (0.79 to 0.95) | 1.13 (1.03 to 1.24) | 1.85 (1.67 to 2.07) | 2.96 (2.53 to 3.47) | <0.01 for all comparisons with eGFR ≥90 |
Values are proportion and HR based on Cox regression analysis (95% CI).
Model 1: adjustment for baseline variables possibly influencing both kidney dysfunction and outcome (age, gender, smoking, hypertension and diabetes).
Model 2: adjustment for variables related to the aetiology and severity of heart failure (heart failure >6 months, ischaemic heart disease, atrial fibrillation, valvular heart disease, dilated cardiomyopathy, previous revascularisation, previous valvular intervention, non-sinus rhythm in the electrocardiogram, heart rate, left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) class, systolic blood pressure and haemoglobin level).
Model 3: adjustment for given treatment (ACE inhibitors, ARB, β-blockers, aldosterone antagonists, statins and cardiac resynchronisation therapy (CRT)).
eGFR, estimated glomerular filtration rate.